Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer

Description

This study investigates fluorine-18-AlphaVBeta6-BP (\[18F\]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that \[18F\]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.

Conditions

Lung Cancer, Lung Cancer Metastatic, Brain Metastases, Non Small Cell Lung Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This study investigates fluorine-18-AlphaVBeta6-BP (\[18F\]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that \[18F\]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool for disease assessment in patients with metastatic NSCLC, including those with brain metastases.

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography for Staging, Response Assessment, and Patient Selection in Metastatic Non-Small Cell Lung Cancer

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer

Condition
Lung Cancer
Intervention / Treatment

-

Contacts and Locations

Sacramento

The University of California Davis Comprehensive Cancer Center, Sacramento, California, United States, 95817

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Men and women age \>18 yrs
  • 2. Biopsy proven NSCLC with brain metastases (treated or untreated)
  • 3. Life-expectancy of ≥3 months in the opinion of the treating physician
  • 4. Available archival tumor tissue (excisional, core, or fine needle aspiration (FNA) is acceptable). Tissue from a metastatic site is preferred when available.
  • 5. Able to tolerate all study procedures, including remain motionless for up to 30-60 minutes per scan
  • 6. Ability to understand and willingness to sign a written informed consent document.
  • 7. Planned to undergo additional cancer-directed therapy followed by standard-of-care re-staging imaging
  • 8. \[18F\]-FDG PET/CT within 21 days of enrollment
  • 9. MRI brain within 21 days of enrollment
  • 10. Eastern Cooperative Oncology Group Performance Status ≤ 2
  • 11. Glomerular filtration rate (GFR) ≥ 60
  • 1. Pregnant or lactating women
  • 2. Prisoners
  • 3. Concurrent malignancy of a different histology that could confound imaging interpretation
  • 4. Patients who cannot undergo PET/CT scanning because of weight limits(\>350lbs)

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, Davis,

Julie L. Sutcliffe, PhD, PRINCIPAL_INVESTIGATOR, The Regents of the University of California (Davis)

Study Record Dates

2025-12-31